WO2003002732A1 - Polypeptides de citrate lyase - Google Patents
Polypeptides de citrate lyase Download PDFInfo
- Publication number
- WO2003002732A1 WO2003002732A1 PCT/SE2002/001301 SE0201301W WO03002732A1 WO 2003002732 A1 WO2003002732 A1 WO 2003002732A1 SE 0201301 W SE0201301 W SE 0201301W WO 03002732 A1 WO03002732 A1 WO 03002732A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- sequence
- citrate lyase
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 100
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 99
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 99
- 108010036824 Citrate (pro-3S)-lyase Proteins 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000000694 effects Effects 0.000 claims abstract description 59
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 47
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 33
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 11
- 230000004129 fatty acid metabolism Effects 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 230000037361 pathway Effects 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 7
- 239000002773 nucleotide Substances 0.000 claims description 56
- 125000003729 nucleotide group Chemical group 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 24
- 239000000523 sample Substances 0.000 claims description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 7
- 101150013191 E gene Proteins 0.000 claims description 6
- 208000035180 MODY Diseases 0.000 claims description 6
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 208000004104 gestational diabetes Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108091081021 Sense strand Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 8
- 210000000577 adipose tissue Anatomy 0.000 abstract description 8
- 239000003596 drug target Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 230000002018 overexpression Effects 0.000 abstract description 2
- 239000013615 primer Substances 0.000 description 34
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 238000010367 cloning Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 238000000636 Northern blotting Methods 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 238000010396 two-hybrid screening Methods 0.000 description 4
- IHVFHZGGMJDGGZ-UHFFFAOYSA-N 2-[2-[2-[3-[[4-[[[5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethylsulfanyl]-2-oxoethyl]-2-hydroxybutanedioic acid Chemical compound OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)(CC(O)=O)C(O)=O)OC1N1C2=NC=NC(N)=C2N=C1 IHVFHZGGMJDGGZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010050785 Citryl-CoA lyase Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 108091060211 Expressed sequence tag Proteins 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 3
- -1 Mazinor) Chemical compound 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 2
- 102000004146 ATP citrate synthases Human genes 0.000 description 2
- 108090000662 ATP citrate synthases Proteins 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- 108010041233 Malyl-CoA lyase Proteins 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000255 pathogenic effect Toxicity 0.000 description 2
- 235000020004 porter Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 101150000003 subB gene Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000589308 Methylobacterium extorquens Species 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 1
- 101100384865 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cot-1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101100168473 Streptomyces griseolus cyp105B1 gene Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940046049 bontril Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- ICFXZZFWRWNZMA-UHFFFAOYSA-N diethylpropion hydrochloride Chemical compound [Cl-].CC[NH+](CC)C(C)C(=O)C1=CC=CC=C1 ICFXZZFWRWNZMA-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 238000003348 filter assay Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940036543 ionamin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 101150063279 subC gene Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229940034887 tenuate Drugs 0.000 description 1
- 229940103784 tepanil Drugs 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the invention relates to isolated nucleic acids encoding mammalian CitE polypeptides, as well as mammalian CitE polypeptides. Furthermore, the invention relates to methods for screening for potential drug targets related to fatty acid metabolism.
- Obesity is a chronic, metabolic disease caused by multiple and complex inherited and acquired factors, including excessive calorie and food intake, decreased physical activity, and genetic influences.
- the defining characteristic is excess body fat.
- Long-term treatment and management are required to achieve and sustain weight loss.
- Today, more than 70 million Americans are overweight.
- Obesity, particularly when associated with unhealthy patterns of body fat distribution results (directly or indirectly) in 300,000 preventable deaths each year in the U.S. and $100 billion in health care costs.
- the obese proportion of the population has increased from 25 percent to 32 percent - a level that may be considered epidemic. The same pattern, though perhaps less pronounced, is also seen in the rest of the western world, including Japan.
- a number of conditions are tightly associated with obesity. These conditions include; cardiovascular disease, high blood pressure, type 2 diabetes, elevated blood cholesterol and triglyceride levels, gout, sleep apnea/obesity hyperventilation syndrome, osteoarthritis of the weight bearing joints and infertility. Obesity also increases the risk for developing certain forms of cancer (e.g., breast and colorectal cancer).
- Adrenergic drugs include Phentermine (Adipex, Fastin, Ionamin), diethylpropion (Tenuate, Tepanil), mazindol (Sanorex, Mazinor), phendimetrazine (Adipost, Bontril, Plegine, Prelu-2), and benzphetamine (Didrex).
- Phentermine Adipex, Fastin, Ionamin
- diethylpropion Tethylpropion
- mazindol Tinu-2
- phendimetrazine Adipost, Bontril, Plegine, Prelu-2
- benzphetamine Didrex
- Orlistat Food and Drug Administration (FDA) for short- term (about 12 weeks) use only.
- Orlistat Xenical
- Orlistat does not act directly on the central nervous system. It inhibits an enzyme (pancreatic lipase) essential to fat digestion.
- the most common side effects of orlistat are intestinal symptoms, including cramping, gas and diarrhea - particularly in patients who ate high-fat foods. These side effects are not pleasant and it is possible that the desire to avoid these side effects encourages people to eat a diet that is lower in fat, thereby helping them to lose weight.
- the inventors of the present invention have surprisingly found a mammalian ortholog to the bacterial CitE.
- a similar enzyme is present in bacteria, but it has never been described in humans.
- This enzyme is transcriptionally regulated in adipose tissue.
- the enzyme is involved in a novel pathway in energy expenditure, downstream of fatty acid metabolism.
- the suggestion that down-regulation of CitE leads to lipolysis and energy expenditure, makes CitE an attractive drug target for treating and/or preventing diseases such as those mentioned above.
- CitE is a cytosolic enzyme that is to be inhibited, makes it an even more attractive drug target.
- the invention refers to the novel mammalian CitE-polypeptide, as well as homologs and functionally equivalent variants thereof.
- the invention refers to the nucleic acid sequence encoding the novel protein and to vectors for expressing the protein in various organisms.
- the invention also refers to methods for expressing the protein in said organisms and for purifying the protein upon overexpression.
- the invention refers to a novel method wherein CitE is used for screening for substances that affect the activity of CitE.
- One further potential application of the human sequence is to use it as a screening target for potential drug molecules.
- the rat sequence may be used as a target for testing the expected efficiency of various substances (which have been screened against a human receptor) in an animal model. This might be relevant, since it is not at forehand clear that a substance working as an inhibitor or enhancer towards the human enzyme also has the same effect on the rat enzyme.
- Fig. 1 is a photograph of a Northern blot analysis showing the expression pattern of the CitE homolog in mouse and rat tissues, respectively.
- Fig. 2 is a graph depicting CitE expression as detected in a human Multiple
- MTE Tissue Expression array
- Fig. 3 is a graph depicting CitE expression as detected in a human Multiple Tissue Northern (MTN).
- MTN Multiple Tissue Northern
- the inventors of the present invention have shown that the stimulation of lipolysis and energy expenditure in mice by the specific ⁇ 3-agonist CL 316,243 induces transcriptional changes in many genes in mouse adipose tissue, as detected by the Affymetrix GeneChip technology.
- One of these genes represented by ESTs only, and which was down-regulated, encodes a protein with apparent homology to bacterial citrate lyase beta chain (CitE), as well as to the Caenorhabditis elegans gene product C01G10.7.
- the bacterial enzyme cleaves citrate to acetyl -moieties and oxaloacetate, and has a structure and molecular mechanism that is distinct from the ATP-dependent citrate lyase.
- citrate The metabolism of citrate is a central pathway in fatty acid metabolism.
- citrate In mammalians, citrate is normally transformed into acetyl-units and oxaloacetate by an ATP-dependent citrate lyase.
- ATP-dependent citrate lyase In bacteria, a different class of citrate lyases (CitE) is known, performing the same reaction, but in an ATP-independent manner. Variants of this bacterial enzyme are described in, for example, Bekal et al. (J. Bacteriology, Feb 1998; 180(3): 647-654), which discloses the purification of Leuconostoc mesenteroides citrate lyase and the cloning and characterization of the corresponding gene cluster.
- Bott discloses anaerobic citrate metabolism and its regulation in enterobacteria
- Arps et al. J Bacteriol, Jun 1993; 175(2): 3776-83 discloses the genetics of malyl coenzyme A lyase in Methylobacterium extorquens AMI.
- RACE Rapid amplification of cDNA Ends
- itE refers to the enzyme citryl-CoA lyase.
- hCitE refers to the human homolog of CitE.
- the hCitE protein consists of 340 amino acids and is shown in (SEQ ID NO:
- the invention features an isolated nucleic acid molecule containing a nucleotide sequence that is at least 60% identical to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5. More preferably, the nucleotide sequence is at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, identical to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5.
- nucleotide sequence that is longer than or equivalent in length to the reference sequence, e.g., SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5
- the comparison is made with the full length of the reference sequence.
- the nucleotide sequence is shorter that the reference sequence, e.g., shorter than SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5
- the comparison is made to a segment of the reference sequence of the same length (excluding any loop required by the homology calculation).
- the nucleotide sequence encodes a polypeptide having citrate lyase activity.
- the nucleotide sequence is identical to SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5.
- the invention features an isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that is at least about 60% identical to a sequence shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, or a fragment thereof.
- the amino acid sequence is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 and has a citrate lyase activity described herein.
- the amino acid sequence can be identical to the sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- a sequential grouping of three nucleotides, a "codon,” codes for one amino acid. Since there are 64 possible codons, but only 20 natural amino acids, most amino acids are coded for by more than one codon. This natural "degeneracy", or
- nucleotide sequences of SEQ ID NO:l, SEQ ID NO:3, and SEQ ID NO:5 are only examples within a large but definite group of DNA sequences that encode the polypeptides described herein.
- an isolated nucleic acid molecule comprising a nucleotide sequence that hybridizes under stringent hybridization conditions to the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, and SEQ ID NO:5, the complete complement of SEQ ID NO:l, SEQ ID NO:3, and SEQ ID NO:5, or a segment thereof as described herein.
- stringent hybridization conditions is known in the art from standard protocols (e.g., Current Protocols in Molecular
- the nucleotide sequence encodes a polypeptide having citrate lyase activity.
- nucleic acid molecule comprising a nucleotide sequence that hybridizes under high stringency conditions to the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5, the complete complement of SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5, or a segment thereof as described herein.
- High stringency conditions refers to hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C.
- the nucleotide sequence encodes a polypeptide having citrate lyase activity.
- nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising a functional domain of the polypeptide of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 described herein, e.g., a citrate lyase domain of a citrate lyase of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the nucleotide sequence encodes a polypeptide having citrate lyase activity.
- nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising at least 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 325, or more contiguous amino acid residues of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the polypeptide comprises an irnmunogenic fragment of at least 20 amino acids of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the nucleotide sequence encodes a polypeptide having citrate lyase activity.
- an "isolated nucleic acid” is a nucleic acid, the structure of which is not identical to that of any naturally occurring nucleic acid or to that of any fragment of a naturally occurring genomic nucleic acid spanning more than three genes.
- the term therefore covers, for example, (a) a DNA which has the sequence of part of a naturally occurring genomic DNA molecule but is not flanked by both of the coding sequences that flank that part of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid incorporated into a vector or into the genomic DNA of a prokaryote or eukaryote in a manner such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, a genomic fragment, a fragment produced by polymerase chain reaction (PCR), or a restriction fragment; and (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.
- a DNA library such as a cDNA or genomic DNA library.
- % identity of two amino acid sequences or of two nucleic acid sequences is determined using the algorithm of Karlin and Altschul (PNAS USA 87:2264-2268, 1990), modified as in Karlin and Altschul, PNAS USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990).
- GappedBLAST is utilized as described in Altschul et al (Nucleic Acids Res. 25:3389-3402, 1997).
- the default parameters of the respective programs e.g., XBLAST and NBLAST
- XBLAST and NBLAST are used to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention.
- the invention features a substantially pure polypeptide having a sequence shown as SEQ ID NO:2, SEQ ID NO:4, or SEQ JD NO:6.
- the invention also includes a polypeptide, or fragment thereof, that differs from the corresponding sequence shown as SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the differences are, preferably, differences or changes at a non-essential residue or a conservative substitution.
- the polypeptide includes an amino acid sequence at least about 60% identical to a sequence shown as SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, or a fragment thereof.
- the amino acid sequence is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 and has a citrate lyase activity described herein.
- the amino acid sequence can be identical to SEQ ID NO:2, SEQ ED NO:4, or SEQ ID NO:6.
- Preferred polypeptide fragments of the invention are at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, or more, of the length of the sequence shown as SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 and have a citrate lyase activity described herein.
- the fragment can be merely an irnmunogenic fragment, e.g., a fragment that can be used to raise monoclonal and/or polyclonal antibodies that specifically bind to a polypeptide of the sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- variants, derivatives, and fragments of a mammalian CitE polypeptide include variants, derivatives, and fragments of a mammalian CitE polypeptide.
- the skilled person will readily be able to determine whether such a variant, derivative, or fragment of a mammalian CitE polypeptide displays CitE activity by subjecting the variant, derivative, or fragment to a standard citrate lyase assay.
- assays are well known in the art (see e.g. Bekal S, et al. Purification of Leuconostoc mesenteroides citrate lyase and cloning and characterization of the citCDEFG gene cluster. J Bacteriol. 1998 Feb;180(3):647-54.).
- the invention encompasses polypeptides carrying modifications such as substitutions, small deletions, insertions or inversions, which polypeptides nevertheless have substantially the biological activities of a citrate lyase.
- a polypeptide encoded by a nucleic acid molecule described herein is included in the invention.
- a “functionally equivalent form” is meant a form of the protein, which possesses essentially the same activity, e.g., a citrate lyase activity, as a full length citrate lyase polypeptide.
- a functionally equivalent form preferably comprises at least 100 amino acids, more preferably at least 200 amino acids, most preferably at least 300 amino acids.
- polypeptide comprising a functional domain of the polypeptide of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 described herein, e.g., a catalytic domain.
- the polypeptide has citrate lyase activity.
- a substantially pure polypeptide comprising at least 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 325, or more contiguous amino acid residues of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the polypeptide comprises an irnmunogenic fragment of at least 20 amino acids of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6.
- the polypeptide has citrate lyase activity.
- substantially pure as used herein in reference to a given polypeptide means that the polypeptide is substantially free from other biological macromolecules.
- the substantially pure polypeptide is at least 75%, 80, 85, 95, or 99% pure by dry weight. Purity can be measured by any appropriate standard method known in the art, for example, by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- the present invention also relates to vectors comprising the nucleic acid molecules of the invention, as well as host cells transformed with such vectors.
- Any of the nucleic acid molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication for propagation in a host cell.
- vectors for the expression of a polypeptide are preferred.
- Such expression vectors include DNA encoding a polypeptide described herein, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene.
- regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences, which control transcription and translation.
- Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding a polypeptide.
- a promoter nucleotide sequence is operably linked to a Cit E DNA sequence if the promoter nucleotide sequence directs the transcription of the Cit E sequence.
- the vector may be any vector, which conveniently may be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
- the vector may be an autonomously replicating vector, e.g., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication (examples of such a vector are a plasmid, phage, cosmid, mini-chromosome or virus).
- the vector may be one which, when introduced in a host cell, is integrated in the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Examples of suitable vectors are a bacterial expression vector and a yeast expression vector.
- the vector of the invention may carry any of the DNA molecules of the invention as defined above.
- a suitable host cell can be a prokaryotic cell, a unicellular eukaryotic cell, or a cell derived from a multicellular organism.
- the host cell can thus, e.g., be a bacterial cell such as an E. coli cell, a cell from a yeast such as Saccharomyces cervisiae or Pichia pastoris, an insect cell, or a mammalian cell, such as HEK293, CHO or an equivalent.
- the methods employed to effect introduction of the vector into the host cell are standard methods well known to a person familiar with recombinant DNA methods.
- Included in the invention is a process for production of a polypeptide described herein, which comprises culturing a host cell as described above under conditions whereby said polypeptide is produced, and optionally recovering said polypeptide, using standard biochemical procedures.
- a further aspect of the invention is a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown in SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5.
- the invention also provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to at least a part of the nucleic acid molecule according to the invention, said part having a sequence shown in SEQ ID NO:l, SEQ ID NO:3, or SEQ ID NO:5.
- Fragments of the nucleic acid molecules described herein, as well as polynucleotides capable of hybridizing to such nucleic acid molecules may be used as a probe or as primers in a polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Such probes may be used, e.g., to detect the presence of nucleic acids coding for Cit E in in vitro assays, as well as in Southern and Northern blots. Cell types expressing Cit E may also be identified by the use of such probes.
- Such procedures are well known, and the skilled artisan will be able to choose a probe of a length suitable to the particular application.
- 5' and 3' primers corresponding to the termini of a desired Cit E nucleic acid molecule are employed to isolate and amplify that sequence using conventional techniques.
- the polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Cit E polypeptide expression.
- Such antibodies may be prepared by conventional techniques. See, for example, Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980).
- Included in the invention is a method for screening for a compound that modulates (increases or decreases) an activity of a citrate lyase, the method comprising: contacting the a polypeptide described herein with a test compound; measuring a citrate lyase activity of the polypeptide in the presence of the test compound; comparing the citrate lyase activity of the polypeptide in the presence of the test compound with the citrate lyase activity of the polypeptide in the absence of the test compound, to thereby determine whether the test compound modulates an activity of a citrate lyase.
- the method can be used, for example, to screen for compounds that increase or decrease the effect or activity of citrate lyase, with the potential of alleviating pathogenic effects of defects in citrate metabolism.
- test compound any suitable molecule being a potential drug target compound.
- the invention provides a kit for carrying out the screening method above, comprising a polypeptide described herein, reagents for performing the method, and optionally instructions for use.
- Included in the invention is a method of identifying an agent that binds to a citrate lyase, the method comprising: contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 with a candidate agent; and determining that the candidate agent binds to the polypeptide, to thereby identify a candidate agent that binds to a citrate lyase.
- the invention also provides a method for disrupting a citrate lyase (Cit E) gene in a non-human embryonic stem cell, the method comprising: providing a nucleotide sequence (e.g., an oligonucleotide) capable ofdisrupting a Cit E gene; and introducing the nucleotide sequence into a non-human embryonic stem-cell under conditions such that nucleotide sequence is homologously recombined into the Cit E gene in the genome of the cell, to produce a cell containing at least one disrupted Cit E allele.
- the invention further provides a non-human transgenic animal expressing reduced levels of Cit E, wherein the Cit E gene has been disrupted by the above method.
- the invention also provides a non-human transgenic animal whose genome comprises an antisense nucleic acid molecule that hybridizes to an mRNA encoding a polypeptide described herein, thereby reducing translation of the polypeptide in the animal.
- a transgenic non-human mammal can e.g. be mammalian animal, such as a mouse, or an animal of the species Caenorhabditis elegans.
- the invention also provides a method for screening for compounds that affect a fatty acid metabolism pathway, the method comprising: providing a non-human transgenic animal described herein; providing a composition comprising a test compound in a form suitable for administration to the non-human animal; administering the test compound to the non-human animal; and determining the effect of the test compound on a fatty acid metabolism pathway in the animal.
- the method can be used to identify compounds that either increase or decrease the effect or activity of any molecule downstream of the a fatty acid metabolism, with the potential of alleviating the pathogenic effects of defects in a fatty acid metabolism.
- the invention refers to the use of a substance identified by a method described herein for use in the treatment of diseases such as diabetes type 2, impaired glucose tolerance and obesity related insulin resistance.
- Impaired insulin resistance and associated glucose intolerance can occur in type 2 diabetes, type 1 diabetes, maturity-onset diabetes of the young (MODY), gestational diabetes, obesity and diseases related to the metabolic syndrome such dyshpedemia, atherosclerosis hypertension. Impaired insulin resistance and glucose intolerance can also occur in non-diabetic individuals and is considered as a predisposing factor for type 2 diabetes.
- Obesity is a condition in which there is an increase in body fat content resulting in excess body weight above accepted norms for age gender height and body build. An excess of mortality that occurs in obese individuals results from diseases that are predisposed by this condition. They include cancer, cardiovascular disease, digestive disease, respiratory disease and type 2 diabetes.
- glucose dependent protein cross-linking occurs at a rate in excess of the norm.
- Excessive non-enzymatic glycosylation of proteins contributes to diabetic complications and complications of aging in non- diabetic humans such as neuropathy, nephropathy, retinopathy, hypertension and atherosclerosis.
- Reducing the insulin resistance and the abnormally high blood glucose level of diabetic subjects benefits the patient by reducing the discomfort of glucosuria and the excessively high mortality and morbidity associated with metabolic syndrome.
- the invention also includes a method for the treatment of a disorder selected from the group consisting of type 2 diabetes, type 1 diabetes, MODY, gestational diabetes, obesity, dyslipidemia, hypertension, cancer, cardiovascular disease, digestive disease, respiratory disease, neuropathy, nephropathy, retinopathy, hypertension, and atherosclerosis, the method comprising administering to an individual in need thereof an amount of an agent effective to modulate (increase or decrease) the expression or activity, e.g., a citrate lyase activity, of a Cit E polypeptide.
- the method can include an additional step of diagnosing an individual as having a disorder described herein.
- the invention refers to a substrate molecule for the enzyme CitE, which substrate molecule is represented by formula I:
- R is CH 2 COOH, H, CH 3 , CH 3 (CH 2 ) n or (CH 2 ) m COOH, whereby n is
- the substrate molecule may be cleaved into acetyl-moieties and oxalo-acetate, in which reaction Cit E functions as a catalyst, as is the case with CitE in bacteria.
- CitE functions as a catalyst
- Malyl-CoA-lyase in bacteria gives the products acetyl-CoA and glyoxalate.
- the mammalian enzyme is expected to give acetyl-CoA and different alfa-keto-carboxyl acids as products, depending on the identity of R in the formula above.
- the invention further refers to a method for cleaving the substrate molecule of formula I, comprising the steps of: providing the substrate molecule; contacting the substrate molecule with an amount of a polypeptide described herein to cleave the substrate molecule.
- Suitable conditions include any conditions appropriate for the reaction to occur, such as the presence of citryl-CoA, 10 mM dithiothreitol, 10 mM MgCl 2 , in a suitable buffer, e.g. 100 mM Tris-HCI (pH 8.5).
- kits for carrying out the method above which kit comprises, in separate vials, the substrate molecule and the Cit E polypeptide, and optionally any other suitable reagents.
- suitable reagents are meant such molecules or chemicals, which allows a suitable condition.
- This can include Citryl-CoA sodium salt or malyl-CoA sodium salt, a suitable reaction buffer, enzymatic reagents to enable a spectrophotometric readout such as malate dehydrogenase and lactate dehydrogenase together with NADH.
- the oxidation by NADH can be measured in a spectrophotometer at 340 nm wavelength.
- the formation of acetyl-CoA in the enzymatic reaction can be measured by reverse- phase high-performance liquid chromatography.
- Example 1 Identification of a mouse EST homologous to C. elesans hypothetical protein C01G10.7 and bacterial Citryl-CoA lyase (CitE gene product) Male C57B1/6 mice, 12 weeks old, were housed under conditions of ambient temperature and free access to water and chow. Either the ⁇ 3-selective agonist CL 316,243 (1 mg/kg) or saline was injected every 12h with 2 doses during a total period of 24 hours. The animals were decapitated 24 h after the experiment was started, and the white adipose tissue was quickly collected and immediately frozen into liquid nitrogen.
- PolyA + mRNAs were extracted from white adipose tissue from control and ⁇ 3- agonist treated mice respectively. They were reverse transcribed using a T7-tagged oligo-dT primer and double-stranded cDNAs were generated. These cDNAs were then amplified and labeled using 7n vitro transcription (IVT) with T7 RNA polymerase and biotinylated nucleotides. The populations of cRNAs obtained after IVT were purified and fragmented by heat to produce a distribution of RNA fragment sizes from approximately 35 to 200 bases.
- IVT 7n vitro transcription
- Affymetrix (Affymetrix, Inc., 3380 Central Exwy, Santa Clara, CA 95051) Mul9K and Mul IK sets of 3 arrays (sub A, subB and subC) and 2 arrays (subA and subB) respectively, were hybridized using the recommended buffer overnight at 45°C with the control or the treated denatured samples. The arrays were then washed and stained with R-phycoerythrin streptavidin with the help of an Affymetrix fluidics station. The cartridges were scanned using a Hewlett-Packard confocal scanner and the images were analyzed with the GeneChip 3.1 software (Affymetrix).
- sequence of protein C01G10.7 was in turn used as query sequence BLAST searches against available protein sequence databanks and found to have significant homology with Leuconostoc mesenteroides citrate lyase ⁇ -chain (citryl-CoA lyase; encoded by CitE).
- the nucleotide sequence of TC20248 was used as query sequence for BLAST searches of the Incyte Genomics (Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, California 94304) mouse Expressed Sequence Tag database (ZooSeq). Several highly scoring sequences were detected.
- #702234264/701883631/701034392 were used to design oligonucleotide primers for cDNA cloning by RACE.
- the full length sequence was obtained by performing both 5' and 3' RACE (c.f. Zhang Y, Frohman MA, Methods Mol Biol 1997;69:61-87 ) on rat brain cDNA.
- the respective sequences of the primers were:
- RACE primer (332) 5'-AAGCTGCCCTGGGTACTGTGGTTTG-3' [SEQ ID NO:7]
- RACE primer (207) 5'-CAGATTGCCGTGGTACAGGAACAGT-3' [SEQ ID NO:8]
- the mRNA substrate was prepared by using the mRNA Direct kit from Dynal AS to prepare rat polyA+ RNA from hypothalamus. The manufacturer's protocol was followed completely. Three hypothalami from normal Sprague-Dawley rats were used for mRNA preparation.
- the RACE reactions were performed using GeneRacer from Invitrogen (cat #L1500-01). The manufacturers manual was followed completely except for precipitations that were performed using pellet paint co-precipitant (Sigma, 69049-3)
- the RACE PCR amplifications were performed as follows; 5 cycles of 94°C, 30 sec; 72°C, 3 min was followed by 5 cycles of 94°C, 30 sec; 70°C, 30 sec; 72°C, 3 min, and 22 cycles of 94°C, 30 sec; 68°C, 30 sec; 72°C, 3 min, and resulted in fragments of approximately 1200 and 500bp for the 5'- and 3'-RACE respectively.
- the first RACE-PCR utilized the 3'RACE primer and the 5'RACE primer for 3' and 5' RACE, respectively.
- the RACE PCR amplifications were performed as shown below and resulted in a band of approximately 500 bp for the 3'-RACE reaction. 5 cycles of 94°C, 30 sec; 72°C, 3 min was followed by 5 cycles of 94°C, 30 sec; 70°C, 30 sec; 72°C, 3 min, and 22 cycles of 94°C, 30 sec; 68°C, 30 sec; 72°C, 3 min.
- the fragments were gel purified using QIAquick Gel Extraction Kit (#1.6122- 50 from Qiagen). The manufacturers protocol was used and samples were eluted in 30 ⁇ l elution buffer. The products were cloned into pCRII-TOPO vector using TOPO TA Cloning Kit (#K4600-01, Invitrogen). Transformants were picked with a toothpick to lOO ⁇ l water. The toothpicks were then transferred to Terrific Broth (#22711-022, Life Technologies) containing 60 ⁇ g/ml ampicillin (#Q100-16, Invitrogen) for making glycerol stocks. The bacterial colonies were transferred to water and boiled for 5min to release plasmid DNA and lO ⁇ l extract was used in colony PCR with vector specific oligonucleotide primers as follows:
- Reverse primer (na 10): 5 * -CCAGTCACGACGTTGTAAA-3' [SEQ ID NO: 10]
- the nucleotide sequence of TC20248 representing EST sequences emanating from a mouse gene encoding a homolog of the C. elegans hypothetical protein C01G10.7 was used as a query sequence in a BLAST run against the GenBank3 mouse EST database in order to retrieve additional EST sequences emanating from this gene and to design oligonucleotides for RACE (Rapid Amplification of cDNA Ends; Matz, M., et al. (1999) Nucleic Acids Res. 27: 1558-1560).
- IMAGE clones #1450860/1889749/1890093 was used to design RACE primers for cloning of the entire part of the cDNA: 3' RACE primer (209) 5'-TTGTGCGTGCTGCGGAACACGGT-3' [SEQ ID NO: 11]
- the RACE was performed using SMART RACE cDNA Amplification Kit from Clontech (#K1811-1). Mouse brain or mouse kidney polyA+ RNA (#6616-1 and #6613-1, Clontech) was used as starting material. The manufacturer's manual was followed completely with the following modifications: (1) PCR cycling in 0,2ml tubes in MJ research Tetrad Thermocycler using the following program: 5 cycles of 94°C, 30 sec; 72°C, 3 min was followed by 5 cycles of 94°C, 30 sec; 70°C, 30 sec; 72°C, 3 min, and 25 cycles of 94°C, 30 sec; 68°C, 30 sec; 72°C, 3 min.
- the RACE on brain cDNA resulted in products of approximately 1600 and 600 base pairs in length for the 3'- and 5'-RACE, respectively.
- kidney cDNA in the reaction resulted in a 600bp fragment for the 5 '-RACE reaction.
- Gel purification of amplified products using QIAquick Gel Extraction Kit (#1.6122-50, Qiagen) was performed following the provided protocol. After purification, the fragments were immediately ligated to pCRII-TOPO vector and transformed into TOPlO-cells, using the TOPO TA cloning kit from Promega (#K4600-01).
- Colony PCR of the resulting bacterial transformants was performed as described above according to the following scheme: heating the sample to 94°C for 5 min; 35 cycles of 94°C, 1 min; 50°C, 1 min; 72°C, 2min, followed by maintaining the sample at 72°C for 10 min.
- the positive clones were subject to preparation of plasmid using QIAprep Spin Miniprep Kit (#1.6103-50) from Qiagen and sequenced as described above.
- the complete nucleotide sequence of the fragments could be assembled with the nucleotide sequence of IMAGE clones #1450860/1889749/1890093 with perfect sequence match (SEQ ID NO: 5).
- the consensus resulted in a continuous nucleotide sequence of 1286 base-pairs (SEQ ID NO:5) containing an open reading frame of 338 amino acids (SEQ ID NO:6) defining the mouse CitE homolog.
- the Incyte Genomics (Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, California 94304) human Expressed Sequence Tag database (LifeSeq Gold) was searched using BLASTP (Altschul et al, J. Molec. Biol., 1990, 215, 403-410, which is inco ⁇ orated herein by reference in its entirety), using the mouse CitE homolog as a query sequence.
- BLASTP Altschul et al, J. Molec. Biol., 1990, 215, 403-410, which is inco ⁇ orated herein by reference in its entirety
- One highly scoring sequence was detected (Sequence ID 7596666H1) that putatively contained the entire open reading frame of the human CitE homolog.
- Physical plasmid DNA corresponding to this sequence was obtained from Incyte Genomics and entire nucleotide sequence was determined of the plasmid insert using standard methods well known in the art, and the resulting sequence is given as SEQ ID NO
- Northern blot hybridizations were performed to examine the expression of rat CitE homolog mRNA.
- the sequence information obtained as described in Example 2 was used to design PCR primers (see below) to be used for probe generation.
- the PCR was performed as follows:
- Reverse PCR primer (332) 5*-AAGCTGCCCTGGGTACTGTGGTTTG- 3' [SEQ ID NO:7]
- 0.25 ⁇ l plasmid of 3'RACE product was mixed with 1.5 ⁇ l fwd primer, 1.5 ⁇ l rev primer, 5 ⁇ l lOx buffer (provided with the enzyme), l ⁇ l lOmM dNTP (#1 969 064 from Boehringer Mannheim), 0.5 ⁇ l Herculase polymerase (#600262, AH Diagnostics), and 40.25 ⁇ l water.
- PCR was performed in a MJ Research PTC- 100 Thermocycler using the following program; heating the sample at 94°C for 5 min, followed by 26 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, 1 min, followed by maintaining the sample at 72°C for 10 min.
- the PCR product of 300bp was purified using QIAquick PCR Purification Kit (#28104) from Qiagen, and radioactively labeled with 32P-dATP (#AA0004/250, Amersham Pharmacia Biotech) was done by random priming using "Strip-EZ DNA Stripable DNA probe synthesis and removal kit" (#1470) from Ambion. Hybridization was carried out on Rat Multiple Tissue Northern Blot (MTN, #7764-1) from Clontech as described in manufacturer's protocol.
- MTN Rat Multiple Tissue Northern Blot
- 0.25 ⁇ l plasmid of 5'RACE product was mixed with 1.5 ⁇ l fwd primer, 1.5 ⁇ l rev primer, 5 ⁇ l lOx buffer (provided with the enzyme), l ⁇ l lOmM dNTP (#1 969 064 from Boehringer Mannheim), 0.5 ⁇ l Herculase polymerase (#600262, AH Diagnostics), and 40.25 ⁇ l water.
- PCR was performed in a MJ Research PTC- 100 Thermocycler using the following program; heating the sample at 94°C for 5 min, followed by 26 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, lmin, followed by maintaining the sample at 72°C for 10 min.
- the PCR product of 200bp was purified using QIAquick PCR Purification Kit (#28104) from Qiagen, and radioactively labeled 32P-dATP (#AA0004/250,
- Incyte clone # 7596666 was mixed with 1.5 ⁇ l fwd primer, 1.5 ⁇ l rev primer, 5 ⁇ l lOx buffer (provided with the enzyme), l ⁇ l lOmM dNTP (#1 969 064 from Boehringer Mannheim), 0.5 ⁇ l Taq polymerase (#27-0799-62, Amersham Pharmacia Biotech), and 40.25 ⁇ l water.
- PCR was performed in a MJ Research PTC- 100 Thermocycler using the following program: heating the sample at 94°C for 5 min, followed by 25 cycles of . 94°C, 1 min; 60°C, 1 min; 72°C, lmin, followed by maintaining the sample at 72°C for 10 min.
- the PCR product of 502bp was purified using QIAquick PCR Purification Kit
- Tissues analyzed in Multiple Tissue Expression number Name Whole brain cerebral cortex frontal lobe parietal lobe occipital lobe temporal lobe pg of cerebral cortex pons cerebellum, left cerebellum, right corpus callosum amygdala caudate nucleus hippocampus medulla oblongata putamen subst nigra accummbens thalamus pituitary spinal cord heart aorta atrium, left atrium, right ventricle, left ventricle, right interventricular septum apex of the heart esophagus stomach duodenum jejunum ileum iloceum appendix colon, ascending colon, transverse colon, descending rectum kidney skeletal muscle spleen thymus peripheral blood leukocyte lymph node bone marrow trachea lung 50 placenta
- MOLT-4 65 leukemia
- Example 8 Recombinant expression of hCitE in Eukaryotic Host Cells A. Expression of hCitE in Mammalian Cells
- a hCitE-encoding polynucleotide is expressed in a suitable host cell using a suitable expression vector and standard genetic engineering techniques.
- the hCitE-encoding sequence described in Example 4 is subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected into Chinese Hamster Ovary (CHO) cells using the transfection reagent FuGENE ⁇ TM (Boehringer-Mannheim) and the transfection protocol provided in the product insert.
- Other eukaryotic cell lines including human embryonic kidney (HEK 293) and COS cells, are suitable as well.
- hCitE are selected by growth in the presence of 100 ⁇ g/ml zeocin (Stratagene, LaJolla, CA).
- hCitE may be purified from the cells using standard chromatographic techniques.
- antisera is raised against one or more synthetic peptide sequences that correspond to portions of the hCitE amino acid sequence, and the antisera is used to affinity purify hCitE protein.
- the hCitE also may be expressed in- frame with a tag sequence (e.g., polyhistidine, hemagluttinin, FLAG) to facilitate purification.
- tag sequence e.g., polyhistidine, hemagluttinin, FLAG
- a polynucleotide molecule having a nucleotide sequence of SEQ ID NO: 1 can be amplified by PCR.
- the forward primer is determined by routine procedures and preferably contains a 5 ' extension which adds the Nde7 cloning site, followed by nucleotides which correspond to a nucleotide sequence of SEQ ID NO: 1.
- the reverse primer is also determined by routine procedures and preferably contains a 5' extension which introduces the Kpn7 cloning site, followed by nucleotides which correspond to the reverse complement of a nucleotide sequence of SEQ ID NO: 1.
- the PCR product is gel purified, digested with Nde7 and Kpn7, and cloned into the corresponding sites of vector pACHTL-A (Pharmingen, San Diego, CA).
- the pAcHTL expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV), and a 6XHis tag upstream from the multiple cloning site.
- a protein kinase site for phosphorylation and a thrombin site for excision of the recombinant protein precede the multiple cloning site is also present.
- baculovirus vectors could be used in place of pAcHTL-A, such as pAc373, pVL941 and pAcIMl .
- Other suitable vectors for the expression of hCitE polypeptides can be used, provided that the vector construct includes appropriately located signals for transcription, translation, and trafficking, such as an in-frame AUG and a signal peptide, as required.
- Such vectors are described in Luckow et al, Virology 170:31-39, among others. The virus is grown and isolated using standard baculovirus expression methods, such as those described in Summers et al.
- pAcHLT-A containing hCitEgene is introduced into baculovirus using the "BaculoGoldTM" transfection kit (Pharmingen, San Diego, CA) using methods established by the manufacturer. Individual virus isolates are analyzed for protein production by radiolabeling infected cells with 35s_ mem ionine at
- Infected cells are harvested at 48 hours post infection, and the labeled proteins are visualized by SDS-PAGE. Viruses exhibiting high expression levels can be isolated and used for scaled up expression.
- a polynucleotide molecule having the nucleotide sequence of SEQ ID NO:l can be amplified by PCR using the primers and methods described above for baculovirus expression.
- the hCitE cDNA is cloned into vector pAcHLT-A (Pharmingen) for expression in Sf9 insect.
- the insert is cloned into the Nde7 and Kpn7 sites, after elimination of an internal Nde7 site (using the same primers described above for expression in baculovirus). DNA is purified with Qiagen chromatography columns and expressed in Sf9 cells.
- Example 9 Antibodies to hCitE Standard techniques are employed to generate polyclonal or monoclonal antibodies to the hCitE protein, and to generate useful antigen-binding fragments thereof or variants thereof, including "humanized” variants. Such protocols can be found, for example, in Sambrook et al. (1989) and Harlow et al. (Eds.), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988). In one embodiment, recombinant hCitE polypeptides (or cells or cell membranes containing such polypeptides) are used as antigen to generate the antibodies.
- one or more peptides having amino acid sequences corresponding to an irnmunogenic portion of hCitE protein are used as antigen.
- the antigen may be mixed with an adjuvant or linked to a hapten to increase antibody production.
- recombinant hCitE or a synthetic fragment thereof is used to immunize a mouse for generation of monoclonal antibodies (or larger mammal, such as a rabbit, for polyclonal antibodies).
- peptides are conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's recommendations.
- the antigen is emulsified with Freund's Complete Adjuvant and injected subcutaneously.
- additional aliquots of hCitE antigen are emulsified with Freund's Incomplete Adjuvant and injected subcutaneously.
- a serum sample is taken from the immunized mice and assayed by western blot to confirm the presence of antibodies that immunoreact with hCitE.
- Serum from the immunized animals may be used as polyclonal antisera or used to isolate polyclonal antibodies that recognize hCitE. Alternatively, the mice are sacrificed and their spleen removed for generation of monoclonal antibodies.
- the spleens are placed in 10 ml serum- free RPMI 1640, and single cell suspensions are formed by grinding the spleens in serum-free RPMI 1640, supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin (RPMI) (Gibco, Canada).
- the cell suspensions are filtered and washed by centrifugation and resuspended in serum-free RPMI.
- Thymocytes taken from three naive Balb/c mice are prepared in a similar manner and used as a Feeder Layer.
- NS-1 myeloma cells kept in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days prior to fusion, are centrifuged and washed as well.
- FBS fetal bovine serum
- spleen cells from the immunized mice are combined with NS-1 cells and centrifuged, and the supernatant is aspirated.
- the cell pellet is dislodged by tapping the tube, and 2 ml of 37 DC PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer-Mannheim) is stirred into the pellet, followed by the addition of serum- free RPMI.
- the cells are centrifuged, resuspended in RPMI containing 15% FBS, 100 ⁇ M sodium hypoxanthine, 0.4 ⁇ M aminopterin, 16 ⁇ M thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and 1.5 x 10 6 thymocytes/ml, and plated into 10 Corning flat-bottom 96-well tissue culture plates (Corning, Corning New York). On days 2, 4, and 6 after the fusion, 100 ⁇ l of medium is removed from the wells of the fusion plates and replaced with fresh medium.
- the fusions are screened by ELISA, testing for the presence of mouse IgG that binds to hCitE. Selected fusion wells are further cloned by dilution until monoclonal cultures producing anti-hCitE antibodies are obtained.
- the interaction trap/two-hybrid library screening method can be used. This assay was first described in Fields et al, Nature, 1989, 340, 245, which is inco ⁇ orated herein by reference in its entirety. A protocol is published in Current Protocols in Molecular Biology 1999, John Wiley & Sons, NY and Ausubel, F. M. et al. 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, which is inco ⁇ orated herein by reference in its entirety. Kits are available from Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3).
- a fusion of the nucleotide sequences encoding all or partial hCitE and the yeast transcription factor GAL4 DNA-binding domain is constructed in an appropriate plasmid (i.e. pGBKT7) using standard subcloning techniques.
- a GAL4 active domain (AD) fusion library is constructed in a second plasmid (i.e. pGADT7) from cDNA of potential hCitE-binding proteins (for protocols on forming cDNA libraries, see Sambrook et al. 1989, Molecular cloning: a laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, which is inco ⁇ orated herein by reference in its entirety).
- the DNA-BD/hCitE fusion construct is verified by sequencing, and tested for autonomous reporter gene activation and cell toxicity, both of which would prevent a successful two-hybrid analysis. Similar controls are performed with the AD/library fusion construct to ensure expression in host cells and lack of transcriptional activity.
- Yeast cells are transformed (ca. 105 transformants/mg DNA) with both the hCitE and library fusion plasmids according to standard procedure (Ausubel, et al., 1992, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, which is inco ⁇ orated herein by reference in its entirety).
- yeast plasmid reporter genes i.e., lacZ, HIS3, ADE2, LEU2
- Yeast cells are plated on nutrient-deficient media to screen for expression of reporter genes. Colonies are dually assayed for ⁇ -galactosidase activity upon growth in Xgal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside) supplemented media (filter assay for ⁇ -galactosidase activity is described in Breeden et al, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, which is inco ⁇ orated herein by reference in its entirety).
- Example 11 Assay for modulators of hCitE enzyme activity
- modulators inhibitors and enhancers
- the modulators that can be identified by this assay are natural substrate, enhancing or inhibitory compounds of hCitE; synthetic analogs and derivatives of natural substrates, enhancers or inhibitors; antibodies, antibody fragments, and/or antibody-like compounds derived from natural antibodies or from antibody-like combinatorial libraries; and/or synthetic compounds identified by high-throughput screening of libraries; and the like. All modulators that bind or modulate hCitE are useful for identifying hCitE activity in tissue samples (e.g., for diagnostic pu ⁇ oses, pathological pu ⁇ oses, and the like).
- Enhancing and inhibitory modulators are useful for up-regulating and down-regulating hCitE activity, respectively, to treat disease states characterized by abnormal levels of hCitE activity.
- the assays may be performed using single putative modulators, and/or may be performed using a known enhancer in combination with candidate inhibitor (or visa versa).
- hCitE activity can be measured by the malate dehydrogenase-catalyzed reduction of oxaloacetate by NADH (modified from: Gribble, A. D., et al. (1996) J. Med. Chem. 39, 3569-3584).
- the standard reaction mixture (100 ⁇ l) contains 100 mM Tris-HCI, pH 8.5, 10 mM MgCl 2 , 10 mM dithiothreitol, 0.14 mM NADH, 2 units of malate dehydrogenase, 5 mM citryl-CoA.
- hCitE a sample of the freshly thawed recombinant protein in a purified form or as a cell-extract (see above) is preincubated with enhancing or inhibitory compounds for 90 min at 4 °C.
- the reaction is started by the addition of 1 ⁇ l of the enzyme preparation to the reaction mixture, and the rate of NADH oxidation can be measured at 340 nm with a spectrophotometer.
- One unit of enzyme can be defined as the amount of enzyme that oxidizes 1 ⁇ mol of NADH per min at 25 °C.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Physics & Mathematics (AREA)
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30081401P | 2001-06-27 | 2001-06-27 | |
US60/300,814 | 2001-06-27 | ||
SE0102290-4 | 2001-06-27 | ||
SE0102290A SE0102290D0 (sv) | 2001-06-27 | 2001-06-27 | New protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002732A1 true WO2003002732A1 (fr) | 2003-01-09 |
Family
ID=26655502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2002/001301 WO2003002732A1 (fr) | 2001-06-27 | 2002-06-27 | Polypeptides de citrate lyase |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003002732A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034799B2 (en) | 2002-03-08 | 2011-10-11 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447954A (en) * | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
WO1999000123A1 (fr) * | 1997-06-26 | 1999-01-07 | Pharmacia & Upjohn Ab | Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite |
-
2002
- 2002-06-27 WO PCT/SE2002/001301 patent/WO2003002732A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447954A (en) * | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
WO1999000123A1 (fr) * | 1997-06-26 | 1999-01-07 | Pharmacia & Upjohn Ab | Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite |
Non-Patent Citations (22)
Title |
---|
BEKAL SADJIA ET AL.: "Purification of leuconostoc mesenteroides citrate lyase and cloning and characterization of the citCDEFG gene cluster", JOURNAL OF BACTERIOLOGY, vol. 180, no. 3, 1998, pages 647 - 654 * |
BROOKS STEPHEN P.J. ET AL.: "Effect of dietary fat on whole body fatty acid synthesis in weanling rats", J. NUTR. BIOCHEM., vol. 10, 1999, pages 291 - 298 * |
DATABASE BIOSIS [online] IRITANI NOBUKO ET AL.: "Lipogenic enzyme gene expression in rat liver during development after birth", Database accession no. (PREV199396063100) * |
DATABASE GENBANK [online] 17 June 2000 (2000-06-17), accession no. EMBL Database accession no. (BE047613) * |
DATABASE GENBANK [online] 17 March 1999 (1999-03-17), accession no. EMBL Database accession no. (AI478544) * |
DATABASE GENBANK [online] 18 March 2002 (2002-03-18), accession no. EMBL Database accession no. (BC023398) * |
DATABASE GENBANK [online] 8 February 2001 (2001-02-08), accession no. EMBL Database accession no. (AK002741) * |
DATABASE GENBANK [online] 8 February 2001 (2001-02-08), accession no. EMBL Database accession no. (AK009345) * |
DATABASE GENBANK [online] 8 March 2002 (2002-03-08), accession no. EMBL Database accession no. (AF428253) * |
DATABASE GENBANK [online] 8 March 2002 (2002-03-08), accession no. EMBL Database accession no. (AF428254) * |
DATABASE GENBANK [online] 9 July 1998 (1998-07-09), accession no. EMBL Database accession no. (AI047476) * |
DATABASE GENBANK [online] 9 July 2002 (2002-07-09), accession no. EMBL Database accession no. (BC034360) * |
DATABASE SWALL [online] 1 December 2001 (2001-12-01), accession no. EMBL Database accession no. (Q96QY4) * |
DATABASE SWALL [online] 1 June 2001 (2001-06-01), Database accession no. (Q9D7D0) * |
DATABASE SWALL [online] 1 June 2002 (2002-06-01), accession no. EMBL Database accession no. (Q8TDH8) * |
DATABASE SWALL [online] 1 June 2002 (2002-06-01), Database accession no. (Q8R4NO) * |
JOURNAL OF BIOCHEMISTRY, vol. 113, no. 5, 1993, pages 519 - 525 * |
KAWAI J. ET AL.: "Functional annotation of full-lenght mouse cDNA collection", NATURE, vol. 409, 2001, pages 685 - 690 * |
KRIKETOS A.D. ET AL.: "(-)-Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state", INT. OBES. RELAT. METAB. DISORD., vol. 23, no. 8, 1999, pages 867 - 873 * |
MORIKAWA JOJI ET AL.: "Molecular cloning of novel mouse and human putative citrate lyase beta-subunit", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, vol. 289, 2001, pages 1282 - 1286 * |
SODERBERG CHARLOTTE ET AL.: "A novel mammalian homologue of a bacterial citrate-metabolizing enzyme", ANN. N.Y. ACAD. SCI., vol. 967, 2002, pages 476 - 481 * |
STRYER: "biochemistry", 1981, FREEMAN & COMPANY, NEW YORK, ISBN: 0-7167-1226-1, pages: 285 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8034799B2 (en) | 2002-03-08 | 2011-10-11 | Philera New Zealand Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU744875B2 (en) | Prostate tumor polynucleotide and antigen compositions | |
KR20080028888A (ko) | 신규 생리 물질 nesfatin과 그 관련 물질, 및그들의 용도 | |
JPH10117789A (ja) | ヒトセリンプロテアーゼ | |
US20020160451A1 (en) | Novel orphan receptors | |
US20040014169A1 (en) | Novel G protein-coupled receptors | |
JP2003521215A (ja) | 83個のヒト分泌タンパク質 | |
WO2003002732A1 (fr) | Polypeptides de citrate lyase | |
US20030104603A1 (en) | Protein | |
JP2002508166A (ja) | ヒトDendriacおよびBrainiac−3 | |
EP1428891A1 (fr) | Nouveau gene nedl-1 | |
US7544485B2 (en) | Baldness related gene and the polypeptide encoded thereby, and uses | |
US5776762A (en) | Obesity associated genes | |
AU753400C (en) | Orphan receptors | |
JP4504682B2 (ja) | 脂肪細胞分化関連遺伝子およびタンパク質 | |
JP2003505084A (ja) | 肥満に関連するウシ神経内分泌蛋白nesp55のヒト相同体、そのポリヌクレオチド及びその使用 | |
CA2268006A1 (fr) | Nouveau gene de semaphorine: la semaphorine w | |
US6811987B1 (en) | Human calcium binding protein and a polynucleotide encoding the same | |
WO2006030761A1 (fr) | Nouveau facteur associé au diabète | |
WO2001066716A1 (fr) | Polypeptide ayant une activite de phosphodiesterase | |
JP2003503062A (ja) | タンキラーゼ2物質および方法 | |
JPH11332579A (ja) | Tsc501遺伝子 | |
US5945321A (en) | Ubiquitin conjugating enzymes 7, 8 and 9 | |
US20040033505A1 (en) | Novel peptide, an n-acetylgalactosamine transferase-28 and the polynucleotide encoding polypeptide | |
US20030186878A1 (en) | Human longevity assurance protein, its coding sequence and their use | |
JP2001352986A (ja) | 新規ポリペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |